You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

OXYBUTYNIN CHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Oxybutynin Chloride, and when can generic versions of Oxybutynin Chloride launch?

Oxybutynin Chloride is a drug marketed by Chartwell Rx, Lannett Co Inc, Pharm Assoc, Pharmobedient Cnsltg, Accord Hlthcare, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Impax Pharms, Norvium Bioscience, Osmotica Pharm Us, Rubicon, Unique, Zydus Pharms, Abhai Llc, Avet Lifesciences, Beximco Pharms Usa, Hibrow Hlthcare, Leading, Novast Labs, Novitium Pharma, Quantum Pharmics, Rising, Strides Pharma, Teva Pharms Usa, Tulex Pharms Inc, Upsher Smith Labs, Usl Pharma, and Watson Labs. and is included in thirty-four NDAs.

The generic ingredient in OXYBUTYNIN CHLORIDE is oxybutynin chloride. There are sixteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oxybutynin Chloride

A generic version of OXYBUTYNIN CHLORIDE was approved as oxybutynin chloride by TEVA PHARMS USA on November 14th, 1988.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OXYBUTYNIN CHLORIDE?
  • What are the global sales for OXYBUTYNIN CHLORIDE?
  • What is Average Wholesale Price for OXYBUTYNIN CHLORIDE?
Drug patent expirations by year for OXYBUTYNIN CHLORIDE
Drug Prices for OXYBUTYNIN CHLORIDE

See drug prices for OXYBUTYNIN CHLORIDE

Drug Sales Revenue Trends for OXYBUTYNIN CHLORIDE

See drug sales revenues for OXYBUTYNIN CHLORIDE

Recent Clinical Trials for OXYBUTYNIN CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Seoul National University HospitalPhase 2
Il-Yang Pharm. Co., Ltd.Phase 2
National Cancer Institute (NCI)Phase 2

See all OXYBUTYNIN CHLORIDE clinical trials

Pharmacology for OXYBUTYNIN CHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for OXYBUTYNIN CHLORIDE
Paragraph IV (Patent) Challenges for OXYBUTYNIN CHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GELNIQUE Gel oxybutynin chloride 10% 022204 1 2014-06-19

US Patents and Regulatory Information for OXYBUTYNIN CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hibrow Hlthcare OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET;ORAL 211062-001 Feb 6, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Unique OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 206121-001 May 27, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Strides Pharma OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET;ORAL 208165-001 Dec 17, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Quantum Pharmics OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET;ORAL 072296-001 Dec 8, 1988 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET;ORAL 071655-001 Nov 14, 1988 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Osmotica Pharm Us OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 078503-003 Feb 4, 2009 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.